Developmental Milestones. Issuer shall ensure that:
Developmental Milestones. Borrower shall ensure that:
Developmental Milestones. Developmental Milestones by COMPANY for a LICENSED PRODUCT in accord with Paragraph 5.3 are as follows: Complete IND enabling study 2020 Initiate animal toxicology study last half 2020 File IND first half 2021 Complete PHASE I CLINICAL TRIAL first half of 2022 Commence PHASE II CLINICAL TRIAL 2024 Commence PHASE III CLINICAL TRIAL 2026 Regulatory approval, US or foreign equivalent 2026
Developmental Milestones. Novartis will notify Xxxxx of the first achievement of any of the Milestone Events set forth below within [***] after their achievement. In addition to (and not in lieu of) royalty payments due under this Agreement, Novartis shall pay to Xxxxx the following one-time, non-refundable, non-recoupable, non- creditable milestone payments no later than [***] after receipt of an invoice for the same, which will be issued following receipt of Novartis’ notice, via wire transfer in immediately available funds to the account specified in writing by Xxxxx: Milestone Event Milestone Payment [***] $ [*** ] [***] $ [*** ] [***] $ [*** ] Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Developmental Milestones. In partial consideration for the license and rights granted to BP herein related to Products, on a Product-by-Product basis, BP will make, or cause to be made, milestone payments to Pieris (each, a “Developmental Milestone Payment”) upon the first achievement of the development and regulatory milestone events set forth in this Section 8.2 (each, a “Developmental Milestone Event”) with respect to such Product. Such Developmental Milestone Payments shall be made within [***] days after achievement of the corresponding Developmental Milestone Event.
Developmental Milestones. (a) Borrower shall have received approval from the FDA to market a generic trientine hydrochloride formulation (based upon the development program currently known as KD034) by December 31, 2019.
Developmental Milestones. Within 30 business days of the achievement of each of the milestone events set forth in the table below (each a “Developmental Milestone”) by Virpax or any Related Party, Virpax shall provide Lipocure with written notice of such achievement and shall pay to Lipocure the corresponding one-time milestone payment set forth next to the applicable milestone in the table below:
Developmental Milestones. Within thirty (30) days after the first achievement of each of the milestone events set forth in the table below by Virpax or any Related Party in relation to a Product, Virpax shall provide MedPharm with written notice of such achievement and shall pay to MedPharm the corresponding one-time milestone payment set forth below (each a “Developmental Milestone”):
Developmental Milestones. Company shall pay to JHU Developmental Milestones as set forth in Exhibit A. The Developmental Milestone payments shall be due, without the need for invoice from JHU, within Ninety (90) days of Company meeting the requirement of each milestone.
Developmental Milestones. The Developmental Milestones under Paragraph 3.4 are: Within thirty (30) days of the issuance of the first U.S. Patent from the PATENT RIGHTS Company will pay to JHU Twenty-five-thousand ($25,000) U.S. Dollars. Within thirty (30) days of the FIRST COMMERCIAL SALE of an Albumin-Bound Protein/Peptide Complex-based research product, company will pay to JHU Twenty-five Thousand ($25,000) U.S. Dollars. Within thirty (30) days of the submission of the first Albumin-Bound Protein/Peptide Complex-based test for regulatory approval in any country, company will pay to JHU One-hundred-thousand ($100,000) U.S. Dollars. Within thirty (30) days of FIRST COMMERCIAL SALE of an Albumin-Bound Protein/Peptide Complex-based approved diagnostic product, company will pay to JHU One-hundred-seventy-five Thousand ($175,000) U.S. Dollars.
